New drug will be sold at around 30% discount to rivals.
But sales of key insulin fall amid biosimilar competition.
Depakine and generics linked with defects including spina bifida.
Costly accounting error for Sanofi.
Sales of MS and eczema drugs could top $4bn by 2022
Repatha cuts cardio events, but not mortality.
Peter Guenter, head of Sanofi’s Diabetes & Cardiovascular business, on the future of chronic disease care.
Companies look to take on Pfizer after series of setbacks.